

Declaration of Governance

Declaration of Compliance and Reporting on Corporate Governance

Epigenomics AG has consistently implemented its corporate governance in consideration of the recommendations and suggestions of the German Corporate Governance Code in its version dated February 7, 2017 until the entry into force of the Code in its version dated March 20, 2020. During the 2020 fiscal year the Executive Board and the Supervisory Board discussed corporate governance matters several times, each time jointly submitting, in April 2020, an interim update of the Declaration of Compliance and, in October 2020, the annual Declaration of Compliance for 2020 pursuant to Section 161 of the German Stock Corporation Act (*Aktiengesetz*, "AktG"). The Declarations were made permanently accessible to the general public on Epigenomics AG's website.

The current Declaration of Compliance of October 2020 reads as follows:

"The Executive Board and the Supervisory Board of Epigenomics AG hereby declare that, since the last declaration of compliance in October 2019, Epigenomics AG has complied with the recommendations of the German Government Commission on the German Corporate Governance Code (hereinafter also "Code") in the version of February 7, 2017 (hereinafter also "Code 2017") until the entry into force of the Code in the version adopted by the German Government Commission on December 16, 2019, on March 20, 2020 (hereinafter also "Code 2020"), with the exceptions set forth below:

Section 3.8 paragraph 3 Code 2017

Epigenomics AG has taken out a D&O policy. The insured persons also include the members of the Supervisory Board. Deviating from Section 3.8 paragraph 3, the D&O policy does not provide for a deductible for members of the Supervisory Board. We did not consider such a deductible to be adequate taking into account the nature of the office as member of the Supervisory Board and the function of the Supervisory Board.

Section 4.1.3 sentence 3 Code 2017

The Company does not have a separate system that employees can use to report, in a protected manner, suspected breaches of the law within the Company. Owing to its size and organization, the Company does not believe that it is necessary to implement such a system. Accordingly, the Company deviated from the recommendation pursuant to Section 4.1.3 sentence 3 Code 2017.

Section 5.1.2 paragraph 1 sentence 2 and paragraph 2 sentence 3 and Section 5.4.1 paragraph 2 sentences 1 and 2 and paragraph 4 Code 2017

In the past, when filling the positions in its bodies, the Executive Board and the Supervisory Board considered the Company-specific situation, and also made allowances for potential conflicts of interest as well as the international activities of the Company through an appropriate diversity of their members as well as the appointment of an adequate number of independent Supervisory Board members. Furthermore, the Supervisory Board determined a maximum term of membership and prepared a profile of skills and expertise for the entire Supervisory Board. In deviation from the recommendations in Section 5.1.2 paragraph 2 sentence 3 and in Section 5.4.1 paragraph 2 sentence 2 Code 2017, we however consider the commitment to institute special age limits for members of the Executive Board and the Supervisory Board as an inadequate limitation of the voting rights of our shareholders. In addition, we are convinced that sweeping requirements for the composition of the Executive Board as requested in Section 5.1.2 paragraph 1 sentence 2 constrain the Supervisory Board inadequately in its selection of suitable members of the Executive Board. The same applies accordingly to the specification of sweeping objectives regarding the composition of the Supervisory Board, as required in Section 5.4.1 paragraph 2 sentences 1 and 2 and assumed in Section 5.4.1 paragraph 4. We strive to achieve an appropriate diversity in the Executive Board and the Supervisory Board and to ensure that an adequate number of independent Supervisory Board members is elected. However, it is ultimately in the corporate interest to appoint as members of the

Executive Board and the Supervisory Board the most suitable male or female candidates. Furthermore, the Supervisory Board has defined gender diversity objectives for the proportion of women in both the Executive Board and the Supervisory Board in accordance with Section 111 paragraph 5 of the Stock Corporation Act (Aktengesetz – AktG). We therefore believe that (additional) sweeping requirements constitute an inadequate limitation of the individual selection of suitable male and female candidates for the Executive Board or the Supervisory Board. Furthermore, a target requirement regarding the composition of the Supervisory Board also inadequately impairs our shareholders' right to elect the Supervisory Board members. Accordingly, we did not comply with these recommendations of the Code 2017.

Sections 5.3.1 sentence 1, and 5.3.3 Code 2017

Due to the size of the Company, the Supervisory Board did not believe that it is necessary to form a Nomination Committee composed exclusively of shareholder representatives which recommends suitable Supervisory Board candidates for the proposals of the Supervisory Board to the general shareholders' meeting. Rather, this task was performed by the full Supervisory Board. Owing to the size of the Company and of the Supervisory Board, the Supervisory Board considers it adequate and appropriate to form only an Audit Committee. In contrast, the implementation of further committees was in the opinion of the Supervisory Board not necessary. Hence, the Company has deviated from the recommendations pursuant to Sections 5.3.1 sentence 1 and 5.3.3 Code 2017.

Furthermore, the Executive Board and Supervisory Board of Epigenomics AG hereby declare that the recommendations of the Code 2020 have been and will be complied with since its entry into force on March 20, 2020, with the following exceptions:

Recommendation A.2 sentence 2 Code 2020

The Company does not have a separate system that employees can use to report, in a protected manner, suspected breaches of the law within the Company. Owing to its size and organization, the Company does not believe that it is necessary to implement such a system. Accordingly, the Company deviates from the recommendation A.2 sentence 2 halvesentence 1 Code 2020.

Recommendations B.1, B.5, C.1 and C.2 Code 2020

In the past, when filling the positions in its bodies, the Executive Board and the Supervisory Board considered the Company-specific situation, and also made allowances for potential conflicts of interest as well as the international activities of the Company through an appropriate diversity of their members as well as the appointment of an adequate number of independent Supervisory Board members. Furthermore, the Supervisory Board determined a maximum term of membership and prepared a profile of skills and expertise for the entire Supervisory Board. In deviation from the recommendations B.5 and C.2 Code 2020, we however consider the commitment to institute special age limits for members of the Executive Board and the Supervisory Board as an inadequate limitation of the voting rights of our shareholders. Accordingly, contrary to recommendations B.5 and C.2 Code 2020, no such age limits are stated in the declaration of governance. In addition, we are convinced that sweeping requirements for the composition of the Executive Board as requested in recommendation B.1 constrain the Supervisory Board inadequately in its selection of suitable members of the Executive Board. The same applies accordingly to the specification of sweeping objectives regarding the composition of the Supervisory Board, as required in recommendation C.1 sentence 1 and sentence 2 Code 2020. We strive to achieve an appropriate diversity in the Executive Board and the Supervisory Board and to ensure that an adequate number of independent Supervisory Board members is elected. However, it is ultimately in the corporate interest to appoint as members of the Executive Board and the Supervisory Board the most suitable male or female candidates. Furthermore, the Supervisory Board has defined gender diversity objectives for the proportion of women in both the Executive Board and the Supervisory Board in accordance with Section 111 paragraph 5 of the Stock Corporation Act (Aktengesetz – AktG). We therefore believe that (additional) sweeping requirements constitute an inadequate limitation of the individual selection of suitable male and female candidates for the Executive Board or the Supervisory Board. Furthermore, a target requirement regarding the composition of the Supervisory Board also inadequately impairs our shareholders' right to elect the Supervisory Board members. Accordingly, we did not comply and will not comply with these recommendations of the Code 2020. In the absence of concrete targets for the composition of the Supervisory Board, the status of the

implementation of such targets is not published in the declaration of governance in deviation from recommendation C.1 sentence 4 of the Code 2020.

Recommendations D.2 sentence 1 and D.5 Code 2020

Due to the size of the Company, the Supervisory Board did not and does not believe that it is necessary to form a Nomination Committee composed exclusively of shareholder representatives which recommends suitable Supervisory Board candidates for the proposals of the Supervisory Board to the general shareholders' meeting. Rather, this task is being performed by the full Supervisory Board. Owing to the size of the Company and of the Supervisory Board, the Supervisory Board considers it adequate and appropriate to form only an Audit Committee. In contrast, the implementation of further committees was and is in the opinion of the Supervisory Board not necessary. Hence, the Company has deviated and will continue to deviate from the recommendations D.2 sentence 1 and D.5 Code 2020.

Recommendation F.2 Code 2020

The Company has published the consolidated financial statements and the Group management report for the fiscal year 2019 on April 29, 2020. Contrary to recommendation F.2 of the Code 2020, the consolidated financial statements and the Group management report have not been published within 90 days from the end of the fiscal year. The deviation has been taken against the background of the general uncertainty expected by the Company because of the coronavirus (COVID-19) and with the intention of ensuring maximum safety of employees, customers, suppliers and fellow citizens. In the upcoming years, the Company intends to publish the consolidated financial statements and the group management report again within 90 days from the end of the fiscal year.

Recommendations G.1, G.3, G.4 and G.11 Code 2020

Section G.I. of the Code 2020 contains new recommendations on the remuneration of the Executive Board. The Company does not fully comply with all new recommendations. The deviations relate to the following recommendations:

- Recommendation G.1 first and third indent Code 2020: The Company's current remuneration system does not contain any provisions on the (individual) maximum remuneration of the members of the Executive Board or on non-financial performance criteria for the granting of variable remuneration components. The Supervisory Board has agreed a maximum amount for each compensation component with each member of the Executive Board. The maximum remuneration can be mathematically derived from this amount. The Supervisory Board has therefore not yet considered an additional separate determination of a maximum remuneration to be reasonable. Non-financial performance criteria are not included in the current remuneration system because the pursuit of certain financial and strategic goals appears to be a priority in view of the Company's situation.
- Recommendations G.3 and G.4 Code 2020: No peer group of other third-party entities has been used to assess the customary level of the current Executive Board remuneration, nor has any vertical compensation comparison been made. In the absence of a peer group of other third-party entities, their composition has not been disclosed. Horizontal and vertical comparison did not appear meaningful so far due to the characteristics of the Company and its size.
- Recommendation G.11 sentence 1 Code 2020: The Supervisory Board takes extraordinary developments into account by means of caps for the individual remuneration components; the caps ensure that the variable remuneration is adjusted "downwards" in the event of extraordinary developments. Conversely, however, in deviation from recommendation G.11, the Supervisory Board does not have the possibility to adjust "upwards" any compensation that is inappropriately low due to extraordinary developments. Until now, the regulatory framework for such an "upward" adjustment option seemed unclear and the practical need did not seem to be urgent.
- Recommendation G.11 sentence 2 Code 2020: The Supervisory Board currently has no possibility to retain or reclaim variable remuneration in justified cases. Against the background of legal uncertainties existing in the past, the introduction of such a possibility has so far been refrained from.

The Supervisory Board will adopt a new remuneration system for the members of the Executive Board and submit it to the Annual General Shareholders' Meeting in 2021 for approval. As part of the development and adoption of the new system, the Supervisory Board will also decide on future compliance with the above recommendations."

Corporate Bodies – Composition and Functioning

As a German stock corporation, Epigenomics AG is subject to the German Stock Corporation Act. Its constituting bodies are the Annual General Shareholders' Meeting (AGM), the Executive Board and the Supervisory Board. The Executive Board and the Supervisory Board each have their own competencies and closely collaborate in a trustworthy manner in steering and supervising the Company.

Annual General Shareholders' Meeting

The purpose of the Annual General Meeting (AGM) is to enable the shareholders (stockholders) to exercise their shareholder rights. The AGM of Epigenomics AG takes place within eight months after the end of the respective fiscal year. According to Section 119 AktG the AGM decides and passes resolutions upon, inter alia, the formal approval of the actions of the Executive Board and the Supervisory Board, the composition of the Supervisory Board, the Company's Articles of Association, capital measures and the appointment of the Company's auditors. Each share of the Company corresponds to one single vote that its holder may exercise at the AGM. All shareholders who are entered in the share register and who registered for the event in a timely manner are eligible to participate in the AGM. Participation and voting by proxy is also possible by granting a power of attorney to an attorney-in-fact of the shareholder's choice.

In due time before each AGM, Epigenomics AG publishes the invitation, the exact wording of the proposed resolutions as well as any reports and/or information required according to the applicable regulations concerning stock corporations in German and English on its website as well as in the Federal Gazette ("*Bundesanzeiger*").

Supervisory Board

According to Section 111 AktG, the Supervisory Board is responsible for consulting and supervision of the Executive Board. Furthermore, the Supervisory Board is responsible for appointing and dismissing members of the Executive Board as well as for the conclusion and termination of their Executive Board service contracts. The Supervisory Board is involved in strategy and planning as well as in all issues of material importance to the Company. All material decisions by the Executive Board require Supervisory Board approval. This includes the approval of the annual budget for each subsequent year, which is being proposed by the Executive Board. Upon discussion with the Supervisory Board, changes may be required and incorporated. The Supervisory Board also issues the mandate for the audit of the annual financial statements to the auditor which has been appointed by the AGM.

The Supervisory Board of Epigenomics AG consists of six members, none of whom has previously been a member of the Company's Executive Board. The Supervisory Board shall have a quorum if at least three of its members participate in the adoption of the resolution. The members of the Supervisory Board, Mr. Heino von Prondzynski as Chairman, Dr. Ann Clare Kessler, Prof. Dr. Günther Reiter and Dr. Helge Lubenow were re-elected at the AGM on May 30, 2018. Mr. Franz Thomas Walt was elected to the Supervisory Board at the AGM on May 15, 2019 and Mr. Alexander Link was newly elected at the AGM on June 12, 2020. The current term of office of all members of the Supervisory Board ends at the end of the AGM that resolves on the formal approval of the actions of the Supervisory Board for the fiscal year ending December 31, 2020. The *curricula vitae* of the members of the Supervisory Board are published on the Company's website (www.epigenomics.com) under "News & Investors" — "Corporate Governance" — "Supervisory Board".

In its meeting on February 6, 2017, the Supervisory Board resolved that the target ratio of one third for the proportion of female members on the Supervisory Board and a deadline of December 31, 2021 for achieving this target. Currently, the Supervisory Board has two female members. This corresponds to a proportion of women of one third and thus meets the defined target ratio.

Furthermore, in its meeting on September 26, 2017, the Supervisory Board determined a profile of skills and expertise for the entire Supervisory Board. The profile of skills and expertise aims at facilitating a

qualified supervision of and advice to the Executive Board by the Supervisory Board and at ensuring that the Supervisory Board's members collectively have the knowledge, skills and professional expertise required to properly perform all duties of the Supervisory Board of a capital market-oriented, internationally operating company in the molecular diagnostics industry. To this end, the members of the Supervisory Board collectively shall have expertise in and /or knowledge of managing an internationally operating company as well as expertise and/ or knowledge in the fields of accountancy and financial reporting, auditing, corporate finance, controlling and risk management, governance and compliance. Moreover, they shall collectively be familiar with the Company's field of business activity and thus have expertise and /or knowledge in the fields of research and development – if possible within the area of technologies that are relevant for the Company and adjacent or related areas – as well as in the fields of production, marketing and sales. The Supervisory Board assumes that its current composition fulfills this profile of skills and expertise. The Supervisory Board also pays attention to diversity.

In its meeting on April 9, 2020, the Supervisory Board resolved that, generally, members should belong to the Supervisory Board for a maximum of twelve years at the end of their term of office. In the future only such people shall be proposed for election to the Supervisory Board who, at the time of election, have not yet been a member of the Supervisory Board for more than twelve years. The members of the Supervisory Board, Mr. Heino von Prondzynski, Dr. Helge Lubenow, Mr. Franz Thomas Walt and Mr. Alexander Link comply with this internally established general time limit. Dr. Ann Clare Kessler and Prof. Dr. Günther Reiter have been members of the Supervisory Board for more than 15 years and will no longer stand for future election to the Supervisory Board. The Supervisory Board regards the adequate number of independent Supervisory Board members and thus – as there are no employees' representatives in the Supervisory Board – of shareholder representatives to be at least three. At the date of this declaration the members of the Supervisory Board, Mr. Heino von Prondzynski, Dr. Ann Clare Kessler, Prof. Dr. Günther Reiter, Dr. Helge Lubenow and Mr. Franz Thomas Walt, are independent members within the meaning of the German Corporate Governance Code. Mr. Alexander Link is a member of the executive board of Deutsche Balaton AG, which directly and indirectly through its subsidiaries holds more than 10% of the voting shares of Epigenomics AG. Beyond that, there are no other personal or business relationships of Mr. Link with the Group, the Company's executive bodies or a shareholder with a significant stake in the Company, which would have to be disclosed according to the German Corporate Governance Code. Apart from this, the Supervisory Board has not determined any concrete objectives regarding its composition.

The working practices of the Supervisory Board have essentially been formally regulated by the rules of procedure that the Supervisory Board has adopted (the rules of procedure are available on the Company's website (www.epigenomics.com) under "News & Investors" - "Corporate Governance"). According to those rules, the Supervisory Board has to meet at least once per calendar quarter. These four quarterly meetings are typically physical meetings, but may possibly also be conducted by telephone. Furthermore, additional meetings can be called. The Executive Board regularly attends the Supervisory Board Meetings and as needed, additional managers can be invited to attend the meetings. The first annual meeting following the completion and audit of the annual financial statements and the consolidated financial statements of the Company – the so-called "Balance Sheet Meeting" – is also attended by the Company's auditor, who reports directly to the Supervisory Board on the audits performed. During this meeting, the Supervisory Board also conducts confidential discussions with the auditors without the Executive Board being present.

The agenda and resolution proposals are communicated well in advance of a Supervisory Board meeting in writing to all participants. If needed at short notice, resolutions are also taken in writing by circular resolution or in telephone or video conferences. All meetings have written minutes and the minutes have to be approved by all members of the Supervisory Board.

The Supervisory Board has established from among its members an Audit Committee, which consists of three members to which advisory, preparatory and monitoring tasks, but no decision-making powers, have been assigned. Prof. Dr. Günther Reiter has been appointed as member and chairman of the Audit Committee, and Dr. Helge Lubenow and Mr. Franz Thomas Walt have been appointed as its other members. The appointments were each made for a term corresponding to the committee members' term of office on

the Supervisory Board. The Supervisory Board has not established any other committees other than the Audit Committee.

The Supervisory Board reviews the efficiency of its activities and those of the Audit Committee once a year. A detailed questionnaire to be completed by the members of the Supervisory Board is used for this purpose.

Once per year, the Supervisory Board reports on its activities to the shareholders; the report is published in the Company's annual report. Moreover, the Chairman of the Supervisory Board regularly reports on the activities of the Supervisory Board to the AGM of the previous business year.

Details of each individual member of the Supervisory Board as well as his/her compensation can be found in the remuneration report, which is part of the management report and group management report in the Company's consolidated financial statements.

Executive Board

The Executive Board is appointed by the Supervisory Board. The Executive Board leads and represents the Company. The Supervisory Board appoints the Executive Board members for a maximum of five years. Multiple successive appointments are permitted.

The Supervisory Board has issued rules of procedure for the Executive Board, which govern in particular the internal working practices and the allocation of responsibilities within the Executive Board and its cooperation with the Supervisory Board.

The Company's Articles of Association do not define a minimum number of Executive Board members. On December 31, 2020, the Executive Board consisted of three members. Mr. Gregory K. Hamilton has been Chief Executive Officer since July 1, 2016 and is appointed in his function until December 31, 2021. Mr. Jorge Garces, Ph.D., has been Executive Board member since December 1, 2017 acting as President and Chief Scientific Officer of the Company. Mr. Garces has left the Company on January 31, 2021. Mr. Albert Weber has been appointed as a member of the Executive Board with responsibility for the areas of finance, human resources and administration since January 1, 2018 until December 31, 2022. Each member of the Executive Board represents the Company jointly with another member of the Executive Board or jointly with an authorized signatory (*Prokurist*). The Supervisory Board has not made use of the possibility to grant sole power of representation to members of the Executive Board.

In its meeting on February 6, 2017, the Supervisory Board resolved that the target ratio of female members on the Executive Board shall be 0% and that the target ratio shall be reached by December 31, 2021. Currently, the ratio of female members on the Executive Board is 0%.

Additionally, the Executive Board resolved at its meeting on February 6, 2017 on target ratios for the proportion of women in the two management levels below the Executive Board and a deadline for their achievement of December 31, 2021. It set a target of 0% for the proportion of women in the first management level and a target of at least one third for the proportion of women in the second management level. Currently, the proportion of women at the first management level is 0% and 75% at the second management level. The set targets of 0% and one third have therefore been achieved before the deadline set.

The Executive Board regularly reports to the Supervisory Board in a timely and comprehensive manner on all significant aspects of the Company's development, its strategy and planning, on risks faced by the Group as well as on compliance related issues, and consults the Supervisory Board prior to any important strategic decisions.

Details of the compensation of members of the Executive Board can be found in the remuneration report, which is part of the management report and the group management report in the Company's consolidated financial statements.

Together with the Executive Board, the Supervisory Board ensures long-term succession planning for the Executive Board. With regard to appointments to the Executive Board, the Supervisory Board gives top priority to the criteria of continuity and professional competence, and these are thus the cornerstones of its succession planning. This is regularly discussed by the Supervisory Board. The current members of the Executive Board are also consulted on these discussions, either individually or as a whole, as well as external experts if necessary. The Supervisory Board draws up a profile of requirements for all Executive Board positions and, if necessary, outlines a pool of candidates. On this basis, potential internal or external candidates are identified, usually also with the support of a renowned recruitment agency.

Transparency

Consistent, comprehensive and timely information of employees, investors, customers, suppliers, authorities and other stakeholders is very important to Epigenomics AG. Reporting on any business activities and the financial situation of Epigenomics AG is done in the annual consolidated and annual financial statements (including the management report and group management report), in half-yearly and quarterly financial reports as well as in press conferences and conference calls. Information is also disseminated in a timely manner by means of press releases and where required by law, via ad hoc announcements. All press releases, presentations and notifications as well as the up-to-date corporate calendar are available at the Company's website (www.epigenomics.com) under "News & Investors".

Black-out Periods and Insider Trading Rules

Generally, trading in primary and derivative financial instruments of the Company by Executive Board members or employees of the Company is permitted only outside of the statutory "closed periods" and further internally defined "black-out" periods. In addition to the black-out periods, the Company's insider trading rules also include prohibitions on notification, recommendation and use with regard to relevant insider information, which may also be relevant for financial instruments issued by other companies. When required, Epigenomics also maintains the insider registers required under Article 18 of the European Market Abuse Regulation (Regulation (EU) No 596/2014, "MAR"). Each internal and external person, who has been identified as an insider, will be informed individually and immediately in writing about the legal requirements and sanctions in connection with insider trading.

Accounting and Auditing

The annual financial statements of Epigenomics AG (single-entity financial statements) are prepared in compliance with the applicable provisions of commercial law and stock corporation law and published in accordance with statutory requirements. The consolidated financial statements of Epigenomics AG are prepared according to commercial law and applying the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), London, as they are to be applied in the European Union (EU) from time to time, and published in accordance with statutory requirements and the stock exchange rules and regulations of the Frankfurt Stock Exchange. After the single-entity financial statements and the consolidated financial statements have been prepared, they are audited by the Company's auditor and adopted and approved by the Supervisory Board. Generally, both financial statements are published within three months after the end of the fiscal year under review.

The auditor reports to the Audit Committee of the Supervisory Board and, at the Balance Sheet Meeting, to the Supervisory Board on all material findings and events derived from the audit that are relevant for the fulfillment of the duties of the Supervisory Board. This also includes any emerging grounds for exclusion or bias.

The half-yearly and quarterly reports and statements of the Company are regularly subjected to a critical review by the auditor. Prior to approval of each release of a half-yearly report or quarterly statement, a meeting of the Audit Committee of the Supervisory Board is held in which the reports awaiting release are analyzed, critically discussed and, if necessary, modified. Participants of these meetings include the auditor,

the members of the Audit Committee, the Senior Vice President of Finance and Accounting and, as the case may be, further internal experts.

Risk Management

Epigenomics is a globally operating listed cancer molecular diagnostics company and as such is subject to many industry and company specific opportunities and risks. In line with the German Corporation Sector Supervision and Transparency Act (*Gesetz zur Kontrolle und Transparenz im Unternehmensbereich, "KonTraG"*), Epigenomics AG has established a comprehensive and effective system to identify early, document, assess, communicate and manage opportunities and risks across all of its functions and operations. The underlying principles and guidelines have been documented in a group-wide risk management policy. The goal of this policy and all related systems is to systematically identify risks at the earliest possible stage, to estimate their likelihood of occurrence as well as their potential qualitative and quantitative impact, and to be able to design and implement effective countermeasures. The risk management system is regularly evaluated and discussed with the auditors of the Company at the Executive Board and Supervisory Board levels.

Additional information on the Company's risk management system, any specific risks faced by the Company and on the accounting related internal control system can be found in the risk report, which is part of the management report and the group management report in the Company's annual/consolidated financial statements.

Compliance Management System

The main features of the Compliance Management System established at the Company are presented in the Company's annual report.